The Short-Term MBT Project (MBT-RCT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03677037|
Recruitment Status : Recruiting
First Posted : September 19, 2018
Last Update Posted : September 7, 2020
|Condition or disease||Intervention/treatment||Phase|
|Borderline Personality Disorder||Other: Short-term MBT Other: Long-term MBT||Phase 3|
Psychotherapy for borderline personality disorder is often lengthy and resource-intensive. Mentalization-based therapy is an example of an evidence-based treatment that currently has empirical support as an 18-months outpatient program for borderline personality disorder. However, this duration is rarely available, and the long and costly treatment combined with a highly prevalent disorder result in insufficient access to evidence-based care.
The trial is an investigator-initiated, single-centre, assessor-blinded, randomized clinical superiority trial of short-term (20 weeks) compared to long-term (14 months) outpatient mentalization-based therapy for borderline personality disorder or subthreshold borderline personality disorder. Participants will be recruited from the Outpatient Clinic for Personality Disorders at Stolpegaard Psychotherapy Centre, Mental Health Services, Capital Region of Denmark. Participants will be assessed at trial intake using the Mini International Neuropsychiatric Interview and the Structured Clinical Interview for DSM-5 Personality Disorders. Participants will be included if they meet a minimum of four DSM-5 criteria for borderline personality disorder. Participants will be assessed blind to treatment allocation at baseline, and at 8, 16, and 24 months after randomization.
The primary outcome is severity of borderline symptomatology assessed using the Zanarini Rating Scale for Borderline Personality Disorder interview. Secondary outcomes include self-harm incidents, functional impairment (Work and Social Adjustment Scale), quality of life (Short-Form Health Survey), and global functioning (Global Assessment of Functioning scale). Psychiatric symptoms (Symptom Checklist 90) will be included as an exploratory outcome. Measures of personality functioning, attachment, group alliance, borderline symptoms and mentalization skills will be included as predictor and mediator variables.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||166 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Investigator, Outcomes Assessor)|
|Official Title:||Short-term Versus Long-term Mentalization-based Therapy for Outpatients With Subthreshold or Diagnosed Borderline Personality Disorder: a Randomized Clinical Trial|
|Actual Study Start Date :||September 24, 2018|
|Estimated Primary Completion Date :||October 15, 2022|
|Estimated Study Completion Date :||October 15, 2022|
Experimental: Short-term MBT
The experimental group is short-term mentalization-based therapy. The treatment program includes 20 weeks of mentalization-based group therapy with conjoined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
Other: Short-term MBT
Short-term mentalization-based therapy
Active Comparator: Long-term MBT
The control group is long-term mentalization-based therapy. The treatment program includes 14 months of weekly mentalization-based group therapy with combined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
Other: Long-term MBT
Long-term mentalization-based therapy
- Change in severity of borderline personality disorder assessed with the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) interview [ Time Frame: Assessed at baseline, and at 8, 16 and 24 months post-randomization ]ZAN-BPD is an investigator-administered interview assessing change in severity of borderline personality disorder over time. Each of the nine DSM-5 criteria for borderline personality disorder are rated on a scale from 0-4, where 4 is the most severe, yielding a total score from 0-36.
- Change in functional impairmment assessed with the Work and Social Adjustment Scale (WSAS) [ Time Frame: Assessed at baseline, and at 8, 16 and 24 months post-randomization ]WSAS is a 5-item questionnaire assessing change in functional impairment. Each item is rated on a scale from 0-8, where 0 is no impairment and 8 is severe impairment, yielding a total score between 0-40.
- Change in quality of life assessed with the Short-Form Health Survey 36 (SF-36) [ Time Frame: Assessed at baseline, and at 8, 16 and 24 months post-randomization ]SF-36 is a questionnaire assessing change in self-reported quality of life over time. The instrument measures eight health dimensions: physical function (PF), role physical (RF), bodily pain (BP), social function (SF) role emotional (RE), general health (GH), vitality (VT) and mental health (MH). The questions related to each dimension are scored on a scale from 0 (worst score) to 100 (best score).
- Change in global functioning assessed with the Global Assessment of Functioning (GAF) [ Time Frame: Assessed at baseline, and at 8, 16 and 24 months post-randomization ]GAF is an investigator-administered rating of change in global functioning over time. Global funtioning is rated on a scale from 0-100 for both symptomatic and functional impairment, yielding two total scores from 0-100, where 100 is no impaitment and 0 is severe impairment.
- Change in amount of self-harm incidents [ Time Frame: Assessed at baseline, and at 8, 16 and 24 months post-randomization ]Proportion of participants with severe self-harm defined as deliberate acts of self-harm resulting in visible tissue damage - data will be collected as both dichotomous data and count data.
- Change in psychiatric symptom distress assessed with the Symptom Checklist 90 (SCL-90) [ Time Frame: Assessed at baseline, and at 8, 16 and 24 months post-randomization ]SCL-90 is a questionnaire assessing change in psychiatric symptom distress over time. All 90 items are rated on a scale from 0-4. The total score is divided by number of items, yielding a total score on the Global Severity Index ranging from 0 to 4, where 4 is the most severe.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03677037
|Contact: Sophie Juul, M.email@example.com|
|Stolpegaard Psychotherapy Centre, Mental Health Services, Capital Region of Denmark||Recruiting|
|Gentofte, Denmark, 2820|
|Contact: Sophie Juul, M.Sc. 004538645324 firstname.lastname@example.org|
|Principal Investigator: Sophie Juul, M.sc|
|Study Director:||Sebastian Simonsen, PhD||Sponsor-Investigator|